Valued at a market cap of $347 million, Terns Pharmaceuticals (TERN) is a clinical-stage biopharma company that develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis, and obesity. Terns is developing a portfolio of products to address serious diseases, including oncology and obesity - the latter of which has sparked some serious interest in the stock lately.
Shares of Terns Pharmaceuticals went public in early 2021, and currently trade over 81% below all-time highs, allowing you to buy the dip. Let’s see if you should hold Terns Pharmaceuticals in your equity portfolio right now.
